|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.26 - 15:39
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street (ZeroHedge)
|
|
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street
Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts.
Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind in the GLP-1 race.
"While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely to be received negatively," RBC Capital Markets analyst Trung Huynh wrote in a note to clients earlier.
In a separate note citing the IQVIA data, Cantor analyst Carter Gould said, "We see slower TRx (total prescriptions) growth ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
